- Home
- RPRX vs COKE Comparison
RPRX vs COKE Comparison
Compare RPRX & COKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- COKE
- Stock Information
- Founded
- RPRX 1996
- COKE 1902
- Country
- RPRX United States
- COKE United States
- Employees
- RPRX N/A
- COKE N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- COKE Beverages (Production/Distribution)
- Sector
- RPRX Health Care
- COKE Consumer Staples
- Exchange
- RPRX Nasdaq
- COKE Nasdaq
- Market Cap
- RPRX 14.2B
- COKE 11.7B
- IPO Year
- RPRX 2020
- COKE N/A
- Fundamental
- Price
- RPRX $31.13
- COKE $1,350.00
- Analyst Decision
- RPRX Strong Buy
- COKE
- Analyst Count
- RPRX 5
- COKE 0
- Target Price
- RPRX $41.60
- COKE N/A
- AVG Volume (30 Days)
- RPRX 4.3M
- COKE 52.5K
- Earning Date
- RPRX 05-08-2025
- COKE 05-05-2025
- Dividend Yield
- RPRX 2.83%
- COKE 0.74%
- EPS Growth
- RPRX N/A
- COKE 60.86
- EPS
- RPRX 1.91
- COKE 69.94
- Revenue
- RPRX $2,263,576,000.00
- COKE $6,899,716,000.00
- Revenue This Year
- RPRX $33.46
- COKE N/A
- Revenue Next Year
- RPRX $4.44
- COKE N/A
- P/E Ratio
- RPRX $16.28
- COKE $19.02
- Revenue Growth
- RPRX N/A
- COKE 3.69
- 52 Week Low
- RPRX $24.05
- COKE $800.76
- 52 Week High
- RPRX $34.20
- COKE $1,460.92
- Technical
- Relative Strength Index (RSI)
- RPRX 33.61
- COKE 53.94
- Support Level
- RPRX $32.26
- COKE $1,268.23
- Resistance Level
- RPRX $34.14
- COKE $1,334.48
- Average True Range (ATR)
- RPRX 0.76
- COKE 32.32
- MACD
- RPRX -0.33
- COKE 4.16
- Stochastic Oscillator
- RPRX 14.00
- COKE 80.38
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About COKE Coca-Cola Consolidated Inc.
Coca-Cola Consolidated Inc distributes, markets and manufactures nonalcoholic beverages. It offer a range of nonalcoholic beverage products and flavors, including both sparkling and still beverages. Sparkling beverages are carbonated beverages and the Company's principal sparkling beverage is Coca Cola. Still beverages include energy products and noncarbonated beverages such as bottled water, ready-to-drink tea, ready-to-drink coffee, enhanced water, juices and sports drinks. The Company has three operating segments: Nonalcoholic Beverages, All Other and Eliminations. key revenue is generated from Nonalcoholic Beverages.